Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Abstract
The aberrant proliferation of tumor cells and abundant vasculature in tumor tissues are closely correlated with receptors that are specifically dysregulated in tumor cells. These tumor-associated targets are critical in early diagnosis and therapy selection. Ligands such as antibodies, proteins, polypeptides and polysaccharides that specifically bind to these targets can significantly improve the detection and cure rate when used as tumor imaging probes or anti-tumor agents. Compared to other targeting ligands, peptides have attracted increasingly more attention in tumor diagnostics and therapeutics because of their small sizes, high affinity, stability, ease of modification and low immunogenicity. Several peptide-based imaging probes and therapeutic agents have already been used in clinical trials. This review summarizes some of the tumor-associated targets and their corresponding peptides, as well as the potential of these peptides in cancer treatment.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Peptides are tumor-specific ligands, usually composed of less than 50 amino acids, with small size, high affinity, good stability, easy modification, and low immunogenicity.
“Peptide is a tumor-specific ligand, usually composed of less than 50 amino acids. It has small size, high affinity, good stability, easy modification and low immunogenicity.217”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [217]
Cited by
Sorted by citations
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131 · see citing works
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073 · see citing works
“217 It has attracted more and more attention in the fi eld of tumor diagnosis and treatment.”
BackgroundSelf-citationNanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113891 · Cited by 295 · see citing works
Molecularly Imprinted Polymer Nanoparticles: An Emerging Versatile Platform for Cancer Therapy
Xu, S., Wang, L., & Liu, Z. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202005309 · Cited by 232 · see citing works
Biomedical polymers: synthesis, properties, and applications
Chen, W., Chen, Q., Chen, Q., Cui, C., Duan, S., Kang, Y., Liu, Y., Liu, Y., Muhammad, W., Shao, S., et al. (2022) · Science China Chemistry · doi:10.1007/s11426-022-1243-5 · Cited by 191 · see citing works
Surface Modification of Lipid-Based Nanoparticles
Xu, Y., Fourniols, T., Labrak, Y., Véronique Préat, A., Beloqui, A., & Rieux, A. D. (2022) · ACS Nano · doi:10.1021/acsnano.2c02347 · Cited by 188 · see citing works
Synthesis and functionalization of hyperbranched polymers for targeted drug delivery
Kavand, A., Anton, N., Vandamme, T., Serra, C. A., & Chan‐Seng, D. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.019 · Cited by 141 · see citing works
“factor receptors, vascular endothelial growth factor receptors, and prostate-specific membrane antigen.[205] Integrins are cell adhesion receptors[206] present on the cytoplasmic side of the lipid bilayer promoting the assembly of cytoskeletal polymers and signaling complexes, but also on the extracellular side of the…”
BackgroundDendrimer nanoparticles for colorectal cancer applications
Carvalho, M. R., Reis, R. L., & Oliveira, J. M. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02289a · Cited by 121 · see citing works
Mesoporous Silica Nanoparticles as Carriers for Therapeutic Biomolecules
Castillo, R. R., Lozano, D., & Vallet‐Regí, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12050432 · Cited by 114 · see citing works
“For example, regarding targeting, those sequences are selected for their affinity toward eukaryotic [101,102] or prokaryotic [103,104] cell receptors.”
BackgroundDevelopments in nanotechnology approaches for the treatment of solid tumors
Venturini, J., Chakraborty, A., Baysal, M. A., & Tsimberidou, A. M. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00656-1 · Cited by 117 · see citing works
“Furthermore, highly sensitive and specific biosensors have been developed for cancer diagnostics [13, 14], with multifunctional nanoparticles engineered to function as both imaging and therapeutic agents, thus paving the way for theragnostic approaches [11].”
Photodynamic Therapy and the Biophysics of the Tumor Microenvironment
Sorrin, A. J., Ruhi, M. K., Ferlic, N. A., Karimnia, V., Polacheck, W. J., Celli, J. P., Huang, H., & Rizvi, I. (2020) · Photochemistry and Photobiology · doi:10.1111/php.13209 · Cited by 101 · see citing works
Drug conjugate-based anticancer therapy - Current status and perspectives
Yang, Y., Wang, S., Ma, P., Jiang, Y., Cheng, K., Yu, Y., Jiang, N., Miao, H., Tang, Q., Liu, F., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215969 · Cited by 100 · see citing works
“Targeting Design” of Nanoparticles in Tumor Therapy
Yang, T., Zhai, J., Hu, D., Yang, R., Wang, G., Li, Y., & Liang, G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091919 · Cited by 84 · see citing works
“At present, a variety of high-affinity receptors have been used for targeted drug delivery, such as transferrin receptor [111], ανβ3 integrin receptor [112], CD44 receptor [60], epidermal growth factor receptor [90] and other receptor targets.”
BackgroundDual-Targeting and Stimuli-Triggered Liposomal Drug Delivery in Cancer Treatment
AlSawaftah, N., Pitt, W. G., & Husseini, G. A. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00066 · Cited by 83 · see citing works
Active Targeted Nanoformulations via Folate Receptors: State of the Art and Future Perspectives
Martín‐Sabroso, C., Torres‐Suárez, A. I., Alonso, M., Fernández-Carballido, A. M., & Fraguas‐Sánchez, A. I. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010014 · Cited by 74 · see citing works
Deng, X., Mai, R., Zhang, C., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113050 · Cited by 72 · see citing works
Recent advances in liposome-based targeted cancer therapy
Fidan, Y. G., Muçaj, S., Timur, S. S., & Gürsoy, R. N. (2023) · Journal of Liposome Research · doi:10.1080/08982104.2023.2268710 · Cited by 73 · see citing works
“Moreover, peptides penetrate tumors better than antibodies due to their moderate affinity for antigens [122,123].”
BackgroundTumor-penetrating peptide for systemic targeting of Tenascin-C
Lingasamy, P., Tobi, A., Kurm, K., Kopanchuk, S., Sudakov, A., Salumäe, M., Rätsep, T., Asser, T., Bjerkvig, R., & Teesalu, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-62760-y · Cited by 70 · see citing works
Molecular imaging: design mechanism and bioapplications
Chen, L., Lyu, Y., Zhang, X., Zheng, L., Li, Q., Ding, D., Chen, F., Li, W., Li, W., Zhang, Y., et al. (2023) · Science China Chemistry · doi:10.1007/s11426-022-1461-3 · Cited by 68 · see citing works
Wu, Y., Sun, M., Wang, D., Li, G., Huang, J., Tan, S., Bao, L., Li, Q., Gao, L., & Si, L. (2019) · Biomaterials Science · doi:10.1039/c9bm00925f · Cited by 62 · see citing works
Drug Nanocrystals for Active Tumor-Targeted Drug Delivery
Lu, L., Xu, Q., Wang, J., Wu, S., Luo, Z., & Lu, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040797 · Cited by 57 · see citing works
Hoppenz, P., Els‐Heindl, S., Kellert, M., et al. (2019) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.9b02406 · Cited by 52 · see citing works
Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy
Xu, W., Ye, C., Qing, X., Liu, S., Lv, X., Wang, W., Dong, X., & Zhang, Y. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100358 · Cited by 50 · see citing works
Li, X., Liu, L., Fu, Y., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.01.003 · Cited by 48 · see citing works
Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides
Simón‐Gracia, L., Hunt, H., & Teesalu, T. (2018) · Molecules · doi:10.3390/molecules23051190 · Cited by 44 · see citing works
“peptide coupled to an indocyanine green dye was intravenously injected for NIR imaging-guided resection of PC of gastric origin in mice [24,45].”
MethodNew Technologies Bloom Together for Bettering Cancer Drug Conjugates
Jin, Y., Zakeri, S. E., Bahal, R., & Wiemer, A. J. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000499 · Cited by 41 · see citing works
“PDCs are potential candidates based on tumor-targeting peptides including somatostatin, bombesin, cyclic-Arg-Gly-Asp peptide, and aptides (Zhao et al., 2018).”
BackgroundThe World of Cell Penetrating: the Future of Medical Applications
Falanga, A., Lombardi, L., Galdiero, E., Genio, V. D., & Galdiero, S. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0140 · Cited by 37 · see citing works
Homing Peptides for Cancer Therapy
Lingasamy, P., & Teesalu, T. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_2 · Cited by 39 · see citing works
Targeted drug conjugates in cancer therapy: Challenges and opportunities
Jia, G., Jiang, Y., & Li, X. (2024) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2024.100048 · Cited by 35 · see citing works
“…in phage display combinatorial libraries, One-bead One--compound (OBOC) combinatorial libraries, and Positional Scanning-synthetic Peptide Combinatorial Libraries (PSSPCLs) have led to the discovery and rational design of numerous novel peptides suitable as carriers for PDCs [129 – 131].”
Al-azzawi, S., & Masheta, D. (2019) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-018-00424-w · Cited by 34 · see citing works
Wang, L., Zhang, D., Li, J., Li, F., Wei, R., Jiang, G., Xu, H., Wang, X., Zhou, Y., & Xi, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113935 · Cited by 30 · see citing works
CMKLR1-targeting peptide tracers for PET/MR imaging of breast cancer
Erdmann, S., Niederstadt, L., Koziolek, E. J., Gómez, J. D. C., Prasad, S., Wagener, A., von Hacht, J. L., Hallmann, S., Exner, S., Bandholtz, S., et al. (2019) · Theranostics · doi:10.7150/thno.34857 · Cited by 29 · see citing works
“biodistribution, tumor penetration and low immunogenic potential [8-11].”
BackgroundZhao, N., Ding, B., Zhang, Y., Klockow, J., Lau, K., Chin, F. T., Cheng, Z., & Liu, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.031 · Cited by 30 · see citing works
“Antibodies and affibodies of protein overexpressed on the cancer cells have been added to the surface of the DDSs shells and coatings for specifically targeting tumor biomarkers [5,6].”
BackgroundSelf-citationCurrent status of targeted microbubbles in diagnostic molecular imaging of pancreatic cancer
Jugniot, N., Bam, R., Meuillet, E. J., Unger, E. C., & Paulmurugan, R. (2020) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10183 · Cited by 26 · see citing works
“Peptide ligands have high potential for clinical applications in a wide range of pathologies.(142) Microbubbles have been reported to be capable of bearing a variety of peptide ligands targeted to endothelial cell adhesion molecules F IGURE 3 Molecularlytargeted microbubble strategies.”
BackgroundPeptide-Assisted Nucleic Acid Delivery Systems on the Rise
Tarvirdipour, S., Skowicki, M., Schoenenberger, C., & Palivan, C. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169092 · Cited by 29 · see citing works
“Compared to antibodies and other tumor-targeting ligands, peptides offer better cell or tissue penetration, high affinity and targeting specificity, low immunogenicity, high stability, and improved pharmacokinetics by chemical modifications [26].”
BackgroundSilva-Pilipich, N., Martišová, E., Ballesteros-Briones, M. C., Hervás‐Stubbs, S., Casares, N., González‐Sapienza, G., Smerdou, C., & Vanrell, L. (2020) · Biomedicines · doi:10.3390/biomedicines8120562 · Cited by 23 · see citing works
“In order to optimize this type of gene therapy, thus increasing the bioavailability of the therapeutic Nb in the tumor, minimizing off-target toxicity, and inhibiting its expression when necessary, different strategies may be pursued in the future: (1) retargeting AAV vector to the desired tissue by modifying capsid p…”
BackgroundRadiolabeled nanobodies for tumor targeting: From bioengineering to imaging and therapy
Piramoon, M., Khodadust, F., & Hosseinimehr, S. J. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188529 · Cited by 23 · see citing works
Li, G., Li, J., Hou, Y., et al. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s321631 · Cited by 21 · see citing works
Phage Display Technology and its Applications in Cancer Immunotherapy
Wang, Y., Gao, S., Lv, J., et al. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520618666181029140814 · Cited by 21 · see citing works
Liu, W., Ma, H., Li, F., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116677 · Cited by 19 · see citing works
Biri‐Kovács, B., Adorján, A. E., Szabó, I., Szeder, B., Bősze, S. E., & Mező, G. (2020) · Biomolecules · doi:10.3390/biom10020183 · Cited by 20 · see citing works
“TTPs can be used as imaging agents or drug delivery systems as well [20].”
High‐throughput screening and biological display technology: Applications in molecular imaging
Luo, R., Liu, H., & Cheng, Z. X. (2023) · iRadiology · doi:10.1002/ird3.11 · Cited by 18 · see citing works
Self-citationAlavi, S., Haeri, A., Mahlooji, I., & Dadashzadeh, S. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02818-8 · Cited by 18 · see citing works
Recent Advances in Therapeutic Peptides for Breast Cancer Treatment
Beheshtirouy, S., Mirzaei, F., Eyvazi, S., & Tarhriz, V. (2020) · Current Protein and Peptide Science · doi:10.2174/1389203721999201117123616 · Cited by 16 · see citing works
Nanotechnology Meets the Tumor Microenvironment: Unlocking New Horizons in Cancer Therapy
Yadav, P., Yadav, A. K., & Bhatia, D. D. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c01120 · Cited by 16 · see citing works
Jeong, J., Cho, H., Moon, Y., Shim, N., Kim, J., Kim, J., Choi, S.-C., Park, J. Y., Kim, Y., & Kim, K. (2025) · Advanced Materials · doi:10.1002/adma.202516974 · Cited by 16 · see citing works
Novel C(Rgdyk)-Based Conjugates of Popam and 5-Fluorouracil for Integrin-Targeted Cancer Therapy
Thysiadis, S., Katsamakas, S., Dalezis, P., et al. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0139 · Cited by 15 · see citing works
Molecularly Imprinted Polymer Nanoparticles: An Emerging Versatile Platform for Cancer Therapy
Xu, S., Wang, L., & Liu, Z. (2020) · Angewandte Chemie · doi:10.1002/ange.202005309 · Cited by 15 · see citing works
Modi, A., Pandey, P., Akhilesh, A., Uniyal, A., Chouhan, D., Agrawal, S., Allani, M., Singh, A. K., Kumar, S., & Tiwari, V. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121796 · Cited by 14 · see citing works
Chaithongyot, S., Duangrat, R., Wootthichairangsan, C., et al. (2019) · Materials Letters · doi:10.1016/j.matlet.2019.126952 · Cited by 13 · see citing works
Chen, H., Zhang, H., & Wang, Z. (2022) · The Analyst · doi:10.1039/d2an00212d · Cited by 12 · see citing works
Conventional Nanosized Drug Delivery Systems for Cancer Applications
Vergallo, C., Hafeez, M. N., Iannotta, D., Santos, H. A., d’Avanzo, N., Dini, L., Cilurzo, F., Fresta, M., Marzio, L. D., & Christian, C. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_1 · Cited by 12 · see citing works
Recent advances in peptide-targeted micelleplexes: Current developments and future perspectives
Costa, D., Santo, D., Domingues, C., Veiga, F., Faneca, H., & Figueiras, A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120362 · Cited by 11 · see citing works
Zhang, Y.-B., Ouyang, M., Wang, H.-L., Zhang, B., Guang, W.-H., Liu, R.-W., Li, X.-C., Shih, T.-C., Li, Z., Cao, J., et al. (2020) · MedComm · doi:10.1002/mco2.48 · Cited by 9 · see citing works
Saini, A., Singh, J., & Kumar, S. (2021) · Organic & Biomolecular Chemistry · doi:10.1039/d1ob00509j · Cited by 10 · see citing works
Targeting MCF-7 Cell Line by Listeriolysin O Pore Forming Toxin Fusion with AHNP Targeted Peptide
Kheirollahi, M., Fotoohi-Ardakani, G., Jaliani, H. Z., et al. (2019) · Advanced Biomedical Research · doi:10.4103/abr.abr_18_19 · Cited by 9 · see citing works
Peptibodies: Bridging the gap between peptides and antibodies
Khezri, H., Mostafavi, M., Dabirmanesh, B., & Khajeh, K. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134718 · Cited by 8 · see citing works
Chen, T., Sun, T., Bian, Y., Pei, Y., Feng, F., Chi, H., Li, Y., Tang, X., Sang, S., Du, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01456 · Cited by 11 · see citing works
Lu, L., Wang, L., Zhao, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108753 · Cited by 8 · see citing works
Noninvasive PET Imaging of a Ga-68-Radiolabeled RRL-Derived Peptide in Hepatocarcinoma Murine Models
Huo, Y., Kang, L., Pang, X., et al. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-018-1234-7 · Cited by 8 · see citing works
Structural Engineering of Fluorescent Self‐Threaded Peptide Probes for Targeted Cell Imaging†
Schreiber, C. L., Zhai, C., & Smith, B. D. (2021) · Photochemistry and Photobiology · doi:10.1111/php.13439 · Cited by 7 · see citing works
“the peptide loops, it will be easy to develop new probes with loop sequences that target other cancer biomarkers (40) such as NGR (targets aminopeptidase N) (41), HAIYPRH (targets transferrin receptor) (42), and SE (targets peptide transporter)”
BackgroundTargeting oncofetal fibronectin and neuropilin-1 in solid tumors with PL2 peptide
Lingasamy, P., Tobi, A., Kurm, K., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-11299-x · Cited by 6 · see citing works
Lew, B., George, M., Blair, S. M., et al. (2022) · Nanoscale Advances · doi:10.1039/d2na00276k · Cited by 6 · see citing works
Screening of an annexin‐A2 ‐targeted heptapeptide for pancreatic adenocarcinoma localization
Ma, H., Jiang, K., Hong, Y., Lei, Y., Fan, Y., Jiang, W., Zhao, L., Liu, J., Yao, W., Xu, J., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13352 · Cited by 7 · see citing works
Guo, R., Wang, H.-M., Dong, X., Hu, Y., Li, J. X., Zang, Y., & Li, X. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01097 · Cited by 5 · see citing works
Gaugaz, F. Z., Chicca, A., Redondo‐Horcajo, M., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051113 · Cited by 5 · see citing works
“Alternative targeting moieties are peptides [5] or small molecules that interact specifically with proteins on tumor cell surfaces (e.”
BackgroundPreclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer
Cuda, T., He, Y., Kryza, T., et al. (2021) · Contrast Media & Molecular Imaging · doi:10.1155/2021/3153278 · Cited by 5 · see citing works
68Ga-Labeled GX1 Dimer: A Novel Probe for PET/Cerenkov Imaging Targeting Gastric Cancer
Yin, J., Xin, B., Zhang, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.750376 · Cited by 4 · see citing works
Homing peptide-based ELISA-like method for the selective and sensitive determination of fibrin
Zhang, Y., Zhang, Y., Zhang, Y., et al. (2019) · Analytical Methods · doi:10.1039/c8ay02630k · Cited by 3 · see citing works
Fatima, M., Alqahtani, F., & Kesharwani, P. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03414-6 · Cited by 2 · see citing works
“…several tumor-targeting peptides have reportedly showed better pharmacokinetics, increased tumor accumulation, increased internalization through receptor-mediated endocytosis, and a stronger affinity for cancer cells that overexpress particular receptors than single peptide-drug conjugates [120].”
Tripathi, A., Vaishnaw, B., Jaishwal, P., Samal, P. K., Verma, A., & Singh, N. (2025) · Current Materials Science · doi:10.2174/0126661454366845250618053301 · Cited by 2 · see citing works
Zuo, Q., Guo, C., Fan, W., et al. (2020) · PubMed · doi:10.3779/j.issn.1009-3419.2020.103.17 · Cited by 1 · see citing works
Ali, H. A.-A., Bejaud, J., Lautram, N., et al. (2025) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2025.100382 · Cited by 1 · see citing works
“The use of tumour-targeting peptides to target the delivery of nanoparticles for cancer therapy have been widely described in the literatures (Kebebe et al., 2018; Zhao et al., 2018).”
Oridonin-loaded liposomes targeting lung cancer: formulation and delivery in vitro and in vivo
Shi, C., Zhang, L., & Hu, P. (2025) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2025.2596294 · Cited by 1 · see citing works
“…more attention in cancer treatment due to their small molecular weight, high affinity and stability, low immunogenicity, and ease of modification [55]. in the present study, we employed soybean lecithin, cholesterol, DsPe-PeG 2000 -Ysa to establish long-circulating liposomes to load ORi to…”
Lu, R., Wu, C., Patil, A., & Wu, H. (2019) · doi:10.1002/9783527344406.ch16 · Cited by 1 · see citing works
Rational Design of Peptides and Protein Molecules in Drug Discovery
Padhy, I., Biswas, A., Nayak, C. K., & Sharma, T. (2024) · doi:10.1002/9781394249190.ch15 · Cited by 1 · see citing works
Korzystka, A. (2019) · University of Birmingham Institutional Research Archive (University of Birmingham)
Al-azzawi, S., & Masheta, D. (2023) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-023-10522-5
Improving antitumor targeting via using PL3 homing peptide and cell-penetrating peptide
Masheta, D., & Al-azzawi, S. (2023) · Research Results in Pharmacology · doi:10.18413/rrpharmacology.9.10028
Couto, C. F., Magela, G. G., Salgarello, L. S., et al. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n6-419
Affinity Materials: From Natural Recognition Elements to Synthetic Counterparts
Moldovean‐Cioroianu, N. S., Usha, S. P., & Altıntaş, Z. (2024) · Springer series on polymer and composite materials · doi:10.1007/978-3-031-67368-9_2
Peptide–Drug Conjugates (PDCs)
Shen, L. (2025) · doi:10.1002/9781394300150.ch3
Lipid-based nanomaterials for enhanced photodynamic therapy
Ricken, Y. S., da Silva, M. M. L., Doring, H. D., Latocheski, E., da Silva, A. C. P., Estevão, B. M., Tessaro, A. L., & de Freitas, C. F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-40431-3.00011-6
Artificial Intelligence in Peptide Drug Discovery
Fu, Y., & Bai, Q. (2026) · Springer eBooks · doi:10.1007/978-3-031-98022-0_7
Engineering calcium-based nanoparticles for cancer treatment
Costa, M., Carvalho, B., Sousa, Â., et al. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115974
Cruz, A., & Bonifácio, V. D. B. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-12166-0_22
- Authors
- Zhao, N., Qin, Y., Liu, H., & Cheng, Z.
- Affiliations
- Stanford Medicine (US)
- Northeastern University (CN)
- Corresponding author
- Liu, Hongguang
- Cheng, Zhen
- Venue
- Anti-Cancer Agents in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2018-03-16
- Volume
- 18
- Issue
- 1
- Pages
- 74-86
- ISSN
- 1568-0118 (ISSN-L)
- 1871-5206
- OpenAlex
- W2606823646
- Cited by
- 86
- References
- 0
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 4 · 2023: 9 · 2022: 13 · 2021: 14 · 2020: 19 · 2019: 10 · 2018: 3 · 2017: 1
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Anti-Cancer Agents in Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Energy (DESC0008397)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chemical Synthesis and Analysis
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- tumor-targeting peptides, molecular imaging probes, peptide therapeutics, cancer diagnosis, tumor vasculature, tumor cell proliferation
- MeSH terms
- Antineoplastic Agents, Humans, Ligands, Neoplasms, Peptides, Molecular Imaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
